Bristol Myers Squibb (CELG-RI) Net Cash Flow (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has 18 years of Net Cash Flow data on file, last reported at -$587.0 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$587.0 million, down 227.06% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.4 billion (down 187.62% YoY), and the FY2025 annual result was -$324.0 million, up 68.7% from the prior year.
• Net Cash Flow rose to -$587.0 million in Q1 2026 per CELG-RI's latest filing, from -$5.5 billion in the prior quarter.
• Over five years, Net Cash Flow peaked at $3.9 billion in Q4 2023 and troughed at -$5.5 billion in Q4 2025.
• A 5-year average of -$279.7 million and a median of -$587.0 million in 2026 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2022 and 2024: Net Cash Flow sank 2768.97% in 2022, then surged 285.59% in 2024.
• A 5-year view of Net Cash Flow shows it stood at $1.3 billion in 2022, then surged by 204.24% to $3.9 billion in 2023, then plunged by 32.84% to $2.6 billion in 2024, then sank by 311.96% to -$5.5 billion in 2025, then soared by 89.35% to -$587.0 million in 2026.
• Business Quant data shows CELG-RI's Net Cash Flow at -$587.0 million in Q1 2026, -$5.5 billion in Q4 2025, and $3.1 billion in Q3 2025.